Lars Carlsson: Machine Learning For Smarter Drug Discovery

Discovering new drugs is becoming more costly. Here you will hear about some examples of how AstraZeneca is trying to improve the drug discovery phases through the use of machine learning.

Lars Carlsson is working in Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden. His main interest lies within machine learning, including everything from theoretical to practical aspects. Lars has been applying various machine-learning algorithms to drug discovery problems since 2004. He is also involved in a number of different research projects granted by EU, SSF and KK stiftelsen.